NCT02264288Phase 2Terminated

Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.

Study sponsor: Celularity Incorporated

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2018-02-27Actual
Enrollment · participants159Actual
Source updated2026-06-12Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 2 fields changed

Primary outcomes · main study measures

Text edit · unverified significance
− Previous value

measure: Complete wound closure of the index ulcer; measure: Safety (adverse events [type, frequency, and severity of AEs, and relationship of AEs to study drug], laboratory abnormalities, and hospitalizations

+ Updated value

measure: Percentage of Subjects With Complete Wound Closure of the Index Ulcer Within 3 Months

The saved outcome text may be shortened. Check the source for full wording.

Primary completion date

Recorded edit
− Previous value

2018-02-28

+ Updated value

2018-02-27

Check registry source